A new study from the University of Maryland Medical Center suggests that many of the medications prescribed to treat dystonic patients might be contributing to a rise in their deaths.
Researchers at the university conducted a review of more than 30 published research papers published between 2006 and 2017 on treatments that are commonly used in the treatment of dystonics.
Researchers found that almost all of the drugs they analyzed were likely to cause side effects and side effects were associated with the increased risk of death.
In addition, many of these medications were associated in some cases with potentially serious side effects, such as severe allergic reactions.
“These findings are consistent with other studies that show that antidepressants can be associated with higher death rates,” said study co-author Dr. Shanna K. Smith, an assistant professor of psychiatry and behavioral sciences.
“The fact that we have found some of these drugs may be more harmful than helpful is worrying.”
The researchers say the drug-related deaths may be caused by patients not getting the medication they were prescribed.
While the medications were not specifically prescribed to dystonians, Smith and her colleagues found that the most commonly prescribed drug was ketamine, a drug used to treat opiate addiction.
Ketamine is a powerful antidepressant that can be prescribed for anxiety and panic disorder and has been approved for use in adults.
“Our study shows that ketamine is associated with a number of adverse outcomes, including increased risk for death, cardiovascular complications, and an increased risk in patients with schizophrenia,” Smith said.
Ketamines are commonly prescribed to manage anxiety and depression in the general population, but Smith said her team found that many patients who were prescribed this medication were not getting it.
“Some patients who are prescribed ketamine may be getting it because they are already having psychotic episodes,” Smith told Newsweek.
“They may be experiencing suicidal thoughts or attempts to commit suicide.”
Smith and co-authors of the new study are studying whether ketamine can be effective in treating dystonias and other psychotic disorders.
Ketamphetamines are currently the only treatment approved for treating dystons.
Smith’s team hopes that other studies will find similar results.
“Ketamine is one of the few medications that is currently approved for the treatment and prevention of psychotic disorders,” Smith added.
“Although ketamine’s efficacy for dystonic patients has not been fully evaluated, we are excited about the potential of ketamine as a treatment for dystoniacs and other psychiatric conditions.”
Smith is not alone in her interest in ketamine.
In 2017, the Food and Drug Administration (FDA) approved the use of ketamphetamine for the relief of symptoms associated with schizophrenia.
The FDA also approved the drug in the future for treatment of other psychotic illnesses such as depression and anxiety.
Kratom is a natural substance that has been used for centuries in Southeast Asia and parts of North and South America, and has gained popularity in the United States as a natural supplement for opioid addiction.
According to the American Psychiatric Association, ketamine was first prescribed for depression in 1965.
In 2007, the FDA approved a ketamine replacement drug called naltrexone.
However, the drug has never been approved by the U.S. Food and Drugs Administration (federal agency) for use as a primary treatment for people with schizophrenia or other mental illnesses.
A number of studies have linked the use and misuse of ketamines to the rise in dystonian deaths.
A recent meta-analysis of more of the published research on ketamine found that it was associated with increased risk.
According the study, ketamines are associated with: Increased risk of suicidal ideation, suicide attempts, and suicide-related hospitalizations, as well as increased risk to self-harm.
Increased risk for suicide and suicidal behavior in the short term, particularly among patients who have comorbidities.
Increased suicide risk in older patients with bipolar disorder and schizophrenia, and in patients who had a history of substance abuse.
Increased death rates among people who had schizophrenia.
In 2016, a group of researchers from the Netherlands found that ketamazine was associated to an increased rate of death among patients with dystonism.
A meta-analytic review of six previous studies published between 1999 and 2017 found that patients taking ketamol had an increased mortality risk, with more than one third of the cases showing elevated mortality.
The study authors noted that it is not clear whether the increased mortality rate was due to ketamine or to other psychiatric or other comorbinant conditions.
The researchers also found that more than two thirds of the ketamine-treated patients had comorbinated symptoms of depression, anxiety, and posttraumatic stress disorder.
Ketamazine and the New York Times article published earlier this month, however, reported that one of those comorbed conditions was dystonie.
A spokesperson for the New Yorker published a statement about the study saying that the article did not provide enough details about the patient population to determine whether the drug caused